VigiLyze

Instant graphical overview of global data to support evaluation of domestic data

VigiLyze login

Get the answers you need

By putting a lot of effort into coding and structuring the VigiBase information, UMC makes it possible to search and analyse the data statistically. VigiLyze is an online resource that delivers useful search and analysis functions and provides a quick and clear overview of VigiBase.

VigiLyze is available free of charge to all member countries of the WHO Programme for International Drug Monitoring. Access can be given to staff members in both national centres and regional centres.
Under-reporting is a known issue in pharmacovigilance and is an argument for countries to complement a small number of cases in a national database with the global database, in order to know more about possible safety concerns.


VigiLyze is used to provide a global, regional or national view of the suspected adverse effects of a medicine. Use it also to find supporting evidence when, for example, assessing one country’s case reports. Access to safety information on drugs that are marketed elsewhere but are not yet on the national market is another benefit.

 

VigiLyze

is a powerful search and analysis tool that provides access to more than 15 million ICSRs in VigiBase, submitted by over 120 countries. VigiLyze includes data on allopathic medicines, traditional medicines (herbals), as well as biological medicines, including vaccines. Results from VigiLyze are generated instantly in tabular and graphical formats.

Read more about VigiLyze

VigiLyze is web-based, accessible and user-friendly – even for first-time users – and it provides an instant graphical overview of global data. All Standardized MedDRA Queries (SMQs) are available to support national centres’ work during the intensive monitoring phase for new drugs.

The Data mining view shows if combinations are reported more frequently than expected and assessors can save searches to follow drugs within their areas of expertise or responsibility, to keep an eye on emerging safety issues.

VigiLyze is particularly valuable when there is limited domestic data and can provide arguments for the importance of pharmacovigilance with information about the performance of other countries.

When a pharmaceutical company seeks a new registration for a drug that has been marketed elsewhere, VigiLyze can provide insight in post-marketing experiences from other countries.

If you have questions about VigiLyze, contact us.

Read more

.